Selection Criteria
We included randomized controlled trials comparing Acanthopanax with placebo or open control (no placebo) in patients with acute ischemic stroke.
Data Collection and Analysis
Two review authors selected trials for inclusion, assessed trial quality, and extracted the data independently.
Main Results
We included 13 trials (962 participants). There were many methodological problems in the design and performance of all the trials. Only 1 trial reported the use of random number tables to divide the treatment and control groups; the remaining 12 trials and all included trials did not report the method of randomization and blinding. The period of follow-up in all included trials ranged from 10 to 30 days. None of the trials reported dropouts or intention-to-treat analysis. None of the trials reported the primary outcome death or dependency during the follow-up period. The outcome measure in all included trials was the improvement of neurological deficit after treatment; Acanthopanax was associated with a significant increase in the number of participants whose neurological impairment improved (risk ratio, 1.22; 95% confidence interval, 1.15 to 1.29). Two trials reported adverse events, including fever, epistaxis, and gingival bleeding; 5 trials reported no adverse events. Assessments of quality of life were not undertaken in all included trials (Figure) .
Implications for Practice
The risk of bias in all included trials was high, and hence the data were not adequate to draw reliable conclusions about the efficacy of Acanthopanax in acute ischemic stroke. The data in this review do not support routine use of Acanthopanax for treatment of acute ischemic stroke.
Implications for Research
This review suggests that Acanthopanax might improve neurological impairment in the treatment of acute ischemic stroke. However, because the observed effects may have been due to bias rather than a true biological effect, further randomized controlled studies are justified to assess the efficacy and safety of Acanthopanax for patients with acute ischemic stroke. The design and performance of future research should consider in particular the use of (1) appropriate methods of randomization to generate the allocation sequence; (2) adequate allocation concealment; (3) blinding of investigator, participants, and outcome assessors; (4) use of standard validated outcome measures measured at some months after randomization; (5) complete follow-up of all randomized participants; and (6) reporting of all deaths and adverse event, critically assessed by standardized monitoring or an effective self-report system.
